BioSpace News Archive

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that it will report its fourth quarter and full year 2021 financial and operating results on Thursday, March 10, 2022, following the close of the U.S. financial markets.

Cognito Therapeutics announced today it will present a virtual symposium featuring a panel of leading neuroscientists to discuss neurophysiological markers in Alzheimer’s Disease progression.

UroGen Pharma Ltd. today announced the submission of an Investigational New Drug application (IND) for UGN-301 (zalifrelimab).

Turning Point Therapeutics, Inc. announced that President and CEO Athena Countouriotis, M.D., will participate in a fireside chat at the 42nd Annual Cowen Healthcare Conference.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will host an event for investors and analysts on Thursday, March 31, 2022 regarding its ovarian cancer program.

SeaSpine Holdings Corporation announced the full commercial launch of NorthStar™ Cervical Facet Fusion and the limited commercial launch of FLASH™ Navigation Lumbar Facet Fusion, the latest orthobiologics solutions tailored to specific procedural needs.

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided highlights of pipeline and business progress.

Jazz Pharmaceuticals plc announced financial results for the full year and fourth quarter of 2021 and provided financial guidance for 2022.

Amneal Pharmaceuticals, Inc. (NYSE: AMRX) (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of the Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.

NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the fourth quarter and year ended December 31, 2021.